8 Aug

What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

WRITTEN BY Mike Benson FEATURED IN Post-Release Earnings Reports

Ionis Pharmaceuticals’ valuation

Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

The above chart compares revenues and earnings per share (or EPS) for Ionis Pharmaceuticals since the first quarter of 2017.

Forward PE

Ionis Pharmaceuticals is trading at a forward PE multiple of ~74.2x on August 8 as compared to the industry average of ~14.2x. Other competitors such as Incyte Pharmaceuticals (INCY), Abbott Laboratories (ABT), and Regeneron Pharmaceuticals (REGN) are trading at a lower forward PE multiple of 34.5x, 20.7x, and 17.9x, respectively, as compared to Ionis.

Forward EV-to-EBITDA ratio

As of August 8, the company is trading at a forward EV-to-revenues multiple of 287.4x as compared to the industry average of 11.5x. Other competitors like Incyte Pharmaceuticals (INCY), Abbott Laboratories (ABT), and Regeneron Pharmaceuticals (REGN) are trading at a lower forward EV-to-EBITDA multiple of 23.8x, ~15.9x, and 13.6x, respectively, as compared to Ionis.

Forward EV-to-revenues ratio

As of August 8, the company is trading at a forward EV-to-revenues multiple of 6.7x compared to the industry average of 4.4x. Other competitors like Incyte Pharmaceuticals (INCY), Abbott Laboratories (ABT), and Regeneron Pharmaceuticals (REGN) are trading at a lower forward EV-to-revenues multiple of 6.2x, ~4.1x, and 5.9x, respectively, as compared to Ionis.

The VanEck Vectors Biotech ETF (BBH) holds 1.4% of its total investments in Ionis (IONS), 5.1% in Regeneron (REGN), 3.7% in Incyte (INCY), and 5.5% in Allergan (AGN).

Latest articles

23 Apr

Why Fiat Chrysler Stock Tanked 5% on Tuesday

WRITTEN BY John Parker

In April so far, Italian-American auto giant Fiat Chrysler Automobiles (FCAU) has outperformed the broader market by a wide margin after underperforming in the first quarter.

Royal Dutch Shell (RDS.A) is slated to release its Q1 2019 results on May 2. Before we review the Q1 2019 estimates, let’s recap Shell’s Q4 2018 performance compared to forecasts.

United Parcel Service (UPS) is scheduled to report its first-quarter earnings results on April 25.

Cleveland-Cliffs (CLF) is expected to report its first-quarter earnings results on April 25.

While the overall cannabis sector experienced weakness on April 23, some stocks managed to gain some positive momentum in the first half of the day.

After being listed on the NASDAQ (QQQ) on March 29, Lyft (LYFT) stock has traded on a negative note so far.